This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Satsuma Pharmaceuticals Zukünftiges Wachstum

We currently don't have sufficient analyst coverage to forecast growth and revenue for Satsuma Pharmaceuticals.

54.7%

Wachstumsrate der Gewinne

68.6%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	21.5%
Wachstumsrate der Einnahmen	60.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	19 May 2023

Keine Aktualisierungen

Gewinn- und Umsatzwachstumsprognosen

MUN:1LV - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	11	-20	N/A	N/A	4
12/31/2024	3	-22	N/A	N/A	4
12/31/2023	N/A	-25	N/A	N/A	4
3/31/2023	N/A	-65	-49	-49	N/A
12/31/2022	N/A	-70	-52	-52	N/A
9/30/2022	N/A	-62	-53	-53	N/A
6/30/2022	N/A	-61	-50	-49	N/A
3/31/2022	N/A	-56	-50	-49	N/A
12/31/2021	N/A	-51	-45	-43	N/A
9/30/2021	N/A	-48	-44	-38	N/A
6/30/2021	N/A	-47	-45	-39	N/A
3/31/2021	N/A	-46	-44	-38	N/A
12/31/2020	N/A	-48	-47	-42	N/A
9/30/2020	N/A	-46	-42	-41	N/A
6/30/2020	N/A	-42	-42	-42	N/A
3/31/2020	N/A	-37	-40	-40	N/A
12/31/2019	N/A	-28	-30	-30	N/A
9/30/2019	N/A	-20	-25	-24	N/A
6/30/2019	N/A	-13	-15	-14	N/A
3/31/2019	N/A	-8	-8	-8	N/A
12/31/2018	N/A	-7	-7	-7	N/A

Einkommen vs. Sparrate: 1LV is forecast to remain unprofitable over the next 3 years.

Ertrag vs. Markt: 1LV is forecast to remain unprofitable over the next 3 years.

Hohe Wachstumserträge: 1LV is forecast to remain unprofitable over the next 3 years.

Einnahmen vs. Markt: 1LV's revenue (60.3% per year) is forecast to grow faster than the German market (3.5% per year).

Hohe Wachstumseinnahmen: 1LV's revenue (60.3% per year) is forecast to grow faster than 20% per year.

Künftige Eigenkapitalrendite: Insufficient data to determine if 1LV's Return on Equity is forecast to be high in 3 years time